VDPHL01 - (302)

July 17, 2026: Veradermics, Incorporated (NYSE: MANE) announced presentation of age-based subgroup analysis data from its randomized, double-blind, placebo-controlled Phase 2/3 Study ‘302’ of VDPHL01 (extended-release oral minoxidil) in >500 males with mild-to-moderate pattern hair loss. The subgroup results (<40 vs ≥40 years) were shared in a poster on July 16, 2026, and are scheduled for oral presentation on July 17, 2026 (10:10 a.m. ET, Mercury Ballroom) at the 2026 American Academy of Dermatology (AAD) Innovation Academy in New York City.

The company also outlined upcoming clinical catalysts in its VDPHL01 program: topline results from Study ‘302’ were previously announced in April 2026; enrollment in the second Phase 3 male trial, Study ‘304,’ was completed in February 2026 with topline results anticipated in 2H 2026. In females, Veradermics said it announced topline data from Study ‘207’ earlier this week, and expects topline data from Study ‘306’ (registration-directed Phase 2/3) in 1H 2027. No subgroup efficacy/safety results were quantified in the provided text.